Assenagon Asset Management
RIGL icon

Assenagon Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Assenagon Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,330
Closed -$548K – 1243
2025
Q3 		$548K Sell
19,330
-220,675
-92% -$6.6M ﹤0.01% 1040
2025
Q2 		$4.5M Sell
240,005
-282,776
-54% -$5.36M 0.01% 596
2025
Q1 		$9.4M Buy
522,781
+112,003
+27% +$2.27M 0.02% 425
2024
Q4 		$6.91M Sell
410,778
-30,987
-7% -$594K 0.01% 608
2024
Q3 		$7.15M Buy
+441,765
New +$5.19M 0.01% 611
2024
Q2 		– Sell
-199,140
Closed -$2.95M – 1482
2024
Q1 		$2.95M Hold
199,140
– – 0.01% 746
2023
Q4 		$2.89M Sell
199,140
-77,844
-28% -$796K 0.01% 797
2023
Q3 		$2.99M Sell
276,984
-85,470
-24% -$1.03M 0.01% 710
2023
Q2 		$4.68M Buy
362,454
+231,725
+177% +$3.13M 0.02% 517
2023
Q1 		$1.73M Buy
130,729
+48,243
+58% +$766K 0.01% 887
2022
Q4 		$1.24M Sell
82,486
-185,499
-69% -$1.7M ﹤0.01% 986
2022
Q3 		$3.16M Buy
267,985
+102,010
+61% +$1.38M 0.01% 587
2022
Q2 		$1.88M Buy
165,975
+90,664
+120% +$1.82M 0.01% 859
2022
Q1 		$2.25M Buy
+75,311
New +$2.04M 0.01% 797
2021
Q4 		– Sell
-1,353
Closed -$49K – 1540
2021
Q3 		$49K Hold
1,353
– – ﹤0.01% 1268
2021
Q2 		$59K Hold
1,353
– – ﹤0.01% 1173
2021
Q1 		$46K Sell
1,353
-47,562
-97% -$1.88M ﹤0.01% 1177
2020
Q4 		$1.71M Sell
48,915
-6,901
-12% -$200K 0.01% 564
2020
Q3 		$1.34M Buy
55,816
+33,473
+150% +$822K 0.01% 691
2020
Q2 		$409K Buy
22,343
+20,747
+1,300% +$373K ﹤0.01% 991
2020
Q1 		$25K Sell
1,596
-11,077
-87% -$236K ﹤0.01% 752
2019
Q4 		$271K Sell
12,673
-49,327
-80% -$1.02M ﹤0.01% 710
2019
Q3 		$1.16M Sell
62,000
-90,578
-59% -$1.87M 0.01% 515
2019
Q2 		$3.98M Buy
152,578
+56,998
+60% +$1.29M 0.03% 339
2019
Q1 		$2.46M Buy
95,580
+37,283
+64% +$852K 0.02% 459
2018
Q4 		$1.34M Buy
+58,297
New +$1.65M 0.02% 572

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management's RIGL Position: Q4 2025 in Review

Assenagon Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2025, closing a stake of 19,330 shares — an estimated $548K sold.

Assenagon Asset Management first reported a position in RIGL in Q4 2018 and held it in 26 quarters. The position peaked at $9.4M in Q1 2025. 193 funds tracked by Wall St. Rank hold RIGL as of Q4 2025.

  • Assenagon Asset Management reported no remaining Rigel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 19,330 Rigel Pharmaceuticals shares in Q4 2025, an estimated $548K.
  • Assenagon Asset Management first reported a position in Rigel Pharmaceuticals in Q4 2018 and held it in 26 quarters.
  • Assenagon Asset Management's Rigel Pharmaceuticals position peaked at $9.4M in Q1 2025.
  • 193 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2025.

Based on Assenagon Asset Management's 13F filing for Q4 2025, filed 9 Jan 2026.